RecruitingNCT06535113

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

Sponsor

Ciceri Fabio

Enrollment

80 participants

Start Date

Feb 22, 2025

Study Type

OBSERVATIONAL

Conditions

Acute Myeloid Leukemia

Summary

The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how a part of the immune system called the inflammasome affects how well patients with acute myeloid leukemia (AML — a type of blood cancer) respond to treatment. Researchers will analyze blood and bone marrow samples to identify patterns that predict treatment outcomes. **You may be eligible if...** - You are 18 years or older - You have a new suspected or confirmed diagnosis of acute myeloid leukemia (AML) - You are able to understand the study and willing to sign consent **You may NOT be eligible if...** - You are under 18 years old - You are unable or unwilling to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERClinical Practice

All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines. There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.

Locations(2)

GOM Bianchi Melacrino Morelli

Reggio Calabria, Calabria, Italy

IRCCS Ospedale San Raffaele

Milan, Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06535113

Related Trials

Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

NCT072434835 locations

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

NCT072959511 location

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649221 locations

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

NCT06672146124 locations

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations